AMNEAL PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
AMNEAL PHARMACEUTICALS, INC. (AMRX) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $114.84 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-02-27
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $114.84M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $163.09M.
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $162.77M.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $121.74M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-12-31 | $114.84M 10-K · filed 2026-02-27 |
| 2024-12-31 | $163.09M 10-K · filed 2025-02-28 |
| 2024-09-30 | $162.77M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $121.74M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $121.64M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $159.06M 10-K · filed 2024-03-14 |
| 2023-09-30 | $164.28M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $163.03M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $162.79M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $163.47M 10-K · filed 2023-03-03 |
| 2022-09-30 | $161.61M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $161.15M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $156.57M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $158.91M 10-K · filed 2022-03-01 |
| 2021-09-30 | $164.38M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $162.71M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $155.16M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $166.69M 10-K · filed 2021-03-01 |
| 2020-09-30 | $166.30M 10-Q · filed 2020-11-06 |
| 2019-12-31 | $144.38M 10-K · filed 2020-03-02 |
| 2018-12-31 | $123.50M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |